Monthly Prescribing Reference

Rapaflo available for benign prostatic hyperplasia (BPH)

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson Watson has launched Rapaflo (silodosin capsules), a selective alpha-1 adrenergic receptor antagonist, for the treatment of the signs and symptoms of ...
Medindia

Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences

CORONA, Calif., Sept. 29 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat investigators presented efficacy and safety data on silodosin, ...
FierceBiotech

Watson Pharmaceuticals Announces New Research Showing RAPAFLO (silodosin) Improves Outcomes for Chronic Prostatitis

- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS - WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly ...
Medindia

Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)

CORONA, Calif., Oct. 8 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat the U.S. Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

Rapaflo approved for BPH

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson The FDA has approved Rapaflo (silodosin, from Watson) for the treatment of benign prostatic hyperplasia (BPH). The FDA has approved Rapaflo (silodosin, ...
FierceBiotech

Watson Pharmaceuticals Receives US FDA Approval for RAPAFLO (silodosin) for the Treatment of Benign Prostatic Hyperplasia

CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the U.S. Food and ...